Stockhub

Editing Sosei Group Corporation

Revision as of 14:49, 7 August 2022 by >Paris (Created page with "Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes...")
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)
Warning: You are editing an out-of-date revision of this page. If you publish it, any changes made since this revision will be lost.
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see Stockhub:Copyrights for details). Do not submit copyrighted work without permission!
Cancel Editing help (opens in new window)
Retrieved from "https://stockhub.co/research/Sosei_Group_Corporation"